Feature | March 03, 2015

Data Published for Pivotal Trial for Tryton Side Branch Stent

Results demonstrate reductions in target vessel failure, side branch percent stenosis

Tryton Side Branch Stent, Pivotal IDE, bifurcation stent, bifurcation stent

March 3, 2015 — Tryton Medical Inc. announced that results from the company’s pivotal clinical trial for the Tryton Side Branch Stent were published in the Journal of the American College of Cardiology. The Tryton Pivotal IDE Trial, which enrolled 704 patients at 67 centers in North America and in 11 countries in the European Union and Israel, was the largest coronary bifurcation study ever conducted.

The Tryton Pivotal IDE trial was a randomized study comparing the Tryton Side Branch Stent to conventional provisional treatment with balloon angioplasty in the side branch. Both study groups were treated with standard drug-eluting stents in the main vessel. Among the 704 patients in the study, fully 60 percent of side-branch vessels treated were smaller than 2.25 mm diameter by quantitative coronary arteriography (QCA). The intended population for the trial included patients presenting with side branch vessels of 2.25 mm diameter or greater by QCA.

Researchers reported that while the study did not meet its primary endpoint of non-inferiority in measures of target vessel failure (TVF) in the overall population of patients treated, post-hoc analysis of outcomes in the intended study population of 289 patients with side branch vessels of 2.25 mm diameter or greater by QCA showed reductions in TVF and side branch percent diameter stenosis with the Tryton stent. In addition, both the Tryton and provisional treatment strategies were shown to have similarly low rates of stent thrombosis and no cardiac deaths reported at nine months.

“The most important finding was the performance of the Tryton Stent in the intended population presenting with complex bifurcations involving significant side branches. In this population, Tryton showed a reduction of TVF within the non-inferiority margin pre-specified for the entire population and significantly reduced side branch percent diameter stenosis,” stated Philippe Genereux, M.D., director of the Core Angiographic Laboratories at the Cardiovascular Research Foundation and the lead author of the manuscript.

For more information: www.tryton.medical.com

Related Content

Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.
Gallery | Cath Lab | October 31, 2019 | Dave Fornell, Editor
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
Overlay Init